

Screening Synthetic Adulterants from Herbal and Dietary Supplements (HDS) Using the Natural Products Application Solution with UNIFI

Dhavalkumar Narendrabhai Patel, Lirui Qiao, Jimmy Yuk, Kate Yu

Waters Corporation



### Abstract

In this application note demonstrates the utility of the Natural Products Application Solution with UNIFI Adulterant Screening Application and the Synthetic Adulterant Library with the analysis of a commercial herbal supplement product.

#### **Benefits**

- The Adulterant Screening Application within the Natural Products Application Solution with UNIFI consists of a set of dedicated workflows
- The Natural Products Application Solution with UNIFI offers a turn-key solution from sample to report that utilizes ultra performance liquid chromatography (UPLC), coupled with a quadrupole time of flight mass spectrometer (Q-Tof MS) for data acquisition
- Significant enhancement in efficiency and ease of use for the screening and identification of synthetic adulterants with minimal requirement for an operator's technical expertise

### Introduction

In recent years, there has been a tremendous increase in the use of natural products in the form of herbal supplements for health benefits and therapeutic effects. Unfortunately, this rise in usage has also led to the increased chance of products being adulterated with synthetic compounds by unscrupulous manufacturers. There have been reports of severe to even fatal cases<sup>1</sup> related to adulteration in herbal products. This has raised global concerns within the natural products community and with various regulatory authorities since it poses a significant risk to consumers.

Liquid chromatography coupled with mass spectrometry (LC–MS) is widely-used for screening herbal supplement products due to their high sensitivity and selectivity, which is critical for analyzing complex matrices typical of natural product samples. However, a major challenge for LC-MS screening has been the lack of robust streamlined workflows that allow quick and easy processing from sample to report.

Here, we demonstrate the utility of the Natural Products Application Solution with UNIFI Adulterant Screening Application and the Synthetic Adulterant Library with the analysis of a commercial herbal supplement product.

This product is a herbal capsule sold by street vendors to alleviate back and joint pain (in rheumatoid arthritis). The label claim indicates that it contains various herbs such as *Picrorhiza kurroa* and *Strychnos nux-vomica Linn*. Using the Natural Products Application Solution with UNIFI Adulterant Screening Application, we were able to automatically detect the existence of any synthetic compounds, and then confirm the identified adulterants through an easy review process, to quickly draw a conclusion.

We showcase a turn-key solution with a streamlined process from sample to report using the Adulterant Screening Application within the Natural Products Application Solution with UNIFI. Figure 1 displays the entire analytical process which integrates all steps (data acquisition, peak picking, library searching, fragment ion confirmation, and report generation) into a streamlined process. Additionally, structure elucidation tools are available to allow further investigation on unknown peaks that did not show matches from the Synthetic Adulterants Library.




Figure 1. The step by step procedure of the Natural Products Application Solution with UNIFI Adulterant Screening Application.

# Experimental

### Sample preparation

1 g of powdered sample (Figure 2) in 10 mL of LC-MS grade methanol solution was sonicated for 20 minutes, followed by centrifugation at RCF of 4472 g for 5 minutes. The supernatant was diluted 250 times with methanol prior to injection (1  $\mu$ L).

Catechin standard mixture (p/n 186007465) was used for the system suitability test. The purchased stock solution was diluted 10x with methanol with a final concentration of 10  $\mu$ g/mL. Injection volume was 1  $\mu$ L.




Figure 2. Powdered anti-inflammatory herbal supplement product obtained from a street vendor.

## LC conditions

LC system:	ACQUITY UPLC I-Class with Flow Through Needle (FTN) Sample Manager
Column:	ACQUITY UPLC HSS T3, 1.8 μm, 2.1 x 100 mm, 40 °C
Sample temp.:	15 °C

Mobile phase A:	Water + 0.1% formic acid
Mobile phase B:	Acetonitrile + 0.1% formic acid

## Gradient table:

Time	Flow rate(mL/min)	Solvent A(%)	Solvent B (%)	Curves
0.0	0.6	98	2	Initial
0.5	0.6	98	2	6
1.0	0.6	95	5	6
5.0	0.6	70	30	6
9.0	0.6	40	60	6
11.0	0.6	40	60	6
12.0	0.6	30	70	6
12.5	0.6	30	70	6
14.5	0.6	0	100	1
15.0	0.6	98	2	1
17.0	0.6	98	2	1

## MS conditions

MS system:	Xevo G2-XS QTof
Acquisition range:	50–1500 Da
Scan time:	0.1 s
Acquisition mode:	ESI+ and ESI-; MS <sup>E</sup> ; resolution mode
Lock mass:	Leucine enkephalin (LE) 0.2 ppm (scan for 0.3 s, interval: 30 s)
Capillary voltage:	1.5 KV (ESI+) 1.5 KV (ESI-)
Cone voltage:	40 V
Collision energy (eV):	Low CE:6 High CE: 10-40
Source temp.:	120 °C
Desolvation temp.:	500 °C
Cone gas flow:	50 L/h
Desolvation gas flow:	1000 L/h
Acquisition time:	17 min

#### Data management

Natural Products Application Solution with UNIFI for instrument control, data mining, and report generation.

# **Results and Discussion**

The Natural Products Application Solution with UNIFI provides turn-key solutions for two types of applications: ingredient profiling for natural product extracts, and adulterants screening for herbal supplements. Each application comes with its own set of workflows. For the Ingredient Profiling Application, a set of 14 preset templates (data filters linked to specified views) are provided in a workflow which incorporates the utility of the Traditional Medicine Library. Detailed utility of this ingredient profiling application had been elaborated in previous applications notes.<sup>2-4</sup>

For the Adulterant Screening Application, a dedicated set of acquisition method templates with generic conditions and parameters is provided for data acquisition. A dedicated workflow containing a set of 7 templates is also provided, which incorporates the utility of the Synthetic Adulterants Library for adulterant screening, reviewing, and confirmation. Finally, a specific report template is provided for automatic report generation. Similarly as with the Ingredient Profiling Application, catechin standard mixture and green tea extract are provided for system suitability testing, and to facilitate familiarization with the utility of the Natural Products Application Solution with UNIFI.

When performing the screening and identification of synthetic adulterants in herbal supplements by LC-MS, one of the most difficult challenges comes from the fact that a fit for purpose library is not available. To solve this challenge, and to help enhance the speed of the entire analytical process, the Synthetic Adulterants Library was created and incorporated into the Adulterants Screening Application as a critical component.

Figure 3 shows the detailed screen capture of the Synthetic Adulterants Library. The library contains a list of synthetic compounds that are frequently found in herbal supplement products as adulterants. These compound names are listed both in English and in simplified Mandarin, and grouped according to their known pharmacological actions. Other relevant information such as chemical structure, molecular formula, average molecular and mono-isotopic exact molecular mass, CAS number, Chemspider ID, and PubChem ID are also included for each compound. In addition, for each of the compound entry, key diagnostic fragment ions are included.

Phenylbutazone (Waters NP Adulterant library. DP)       Image: Compound         Property       Value         Rem type       Compound         Rem description       3/4         UPAC name       4 butyl-12-diptenylpyrazolidine-35-dione         Formula       C19+20N2O2         Average molar mass       308.3743         Monoisotopic mass       308.1525         Rem tag       Filk, And-inflammatory         InCh       (5)C19+20N2O2/2-2-3-14-17-18/27/20         InCh       (5)C19+20N2O2/2-2-3-14-17-18/27/2		Select Item Tags					Library	
Pierrylbutzzone (Waters NP Adulterant library DP)       Waters NP Adulterant Library DP)         Property       Value         Item description       3A         Item description       3A         Item description       3A         Item description       3A         Item description       0         Item description       0         Average molar mass       308.3743         Monoisotopic mass       308.3743         Monoisotopic mass       308.1525         Item tag       fifik, Anti-inflammatory         IteCh       155/c194/2002/21-23-34-137-18(22)20         IteCh       155/c194/2002/21-23-34-137-18(22)20         IteCh time fragmentation type       Mass (m/2)         Monoisotopic messults *       0         Itention technique       Itention internique         Itention technique       0.000 met         Itention technique       0.000 met         Itention technique       0.000 met      <		Create Modify Delete	🖹 🖸 🖬 🕶 🖗			y Items • Library Item Editor	Home • Manage Library	\$-(
Properly       Value         Item type       Compound         Rem description       324         UPAC name       4-butyl-12-diphenylyyrazolidine-35-dione         Formula       C19H20N202         Hill formula       C19H20N202         Hill formula       C19H20N202         Average molar mass       308.3743         Monoisotopic mass       308.3525         Item tag       #Ext. Anti-inflammatory         ISC: 19N200202(-1,2-3-14.17-18/22/20)       ISC: 19N200202(-1,2-3-14.17-18/22/20)         InCNI       ISC		Traditional Chinese Medicines	🔭 Tools 👻 🛋			P Adulterant library_DP]	henylbutazone [Waters NP	Phe
Item type       Compound         Item type       Compound         Item description       Anabolic steroid         UPAC name       4-butyl-12-diphenyloyrazolidine-35-dione         Formula       C19420N202         Hill formula       C19420N202         Average molar mass       308.3743         Monoisotopic mass       308.1525         Item tag       JEX, Anti-inflammatory         ItsC/19420N202/L-2-3-14-17-18(2220)       InChi         ItsC/19420N202/L-2-3-14-17-18(2220)       InChi         ItsC/19420N202/L-2-3-14-17-18(2220)       InChi         ItsC/19420N202/L-2-3-14-17-18(220)       Intimation         ItsC/19420N202/L-2-3-14-17-18(220)       ItsC/19420N202/L-2-3-14-17-18(20)         ItsC       ItsC/19420N202/L-2-3-14-17-18(20)         ItsC       ItsC/19		Pharmacological actions						
Item description         IUPAC name       4-butyl-12-diphenylpyrazolidine-35-dione         Formula       C19420N202         Hill formula       C19420N202         Average molar mass       308.3743         Monoisotopic mass       308.1525         Item tag       Fille/Anti-inflammatory         InCNI       IS/C1940N202(1-2-31.417-1822)20 (16-12-8-5-9-13-16/n+13),174(2-3),4442,1H3         InCNI       IS/C1940N202(1-2-31.417-1822)20 (16-12-8-5-9-13-16/n+13),174(2-3),4442,1H3         Monoisotopic mass       308.1525         InCNI       IS/C1940N202(1-2-31.442,1H3 (16-12-8-5-9-13-16/n+13),174(2-3),4442,1H3         Monoisotopic mesults*       Math-Inflammatory         Monoisotopic mesults       Math-Inflammatory         IncNI       Intromute model, Instrument model,	31		3A					
IUPAC name       4-butyl-12-dipheny(pyrazolidine-3.5-dione         Formula       C19H20N202         Hill formula       C19H20N202         Average molar mass       308.3743         Monoisotopic mass       308.1525         Item tag       #JUK, Anti-inflammatory         InCNI       [15-10-6-4-7:11-15)21(19(17)23) (15-10-6-4-7:11-15)21(19(17)23) (16-12-8-5-9:13-16/h4-13.17/H2-3.314H2.1H3)         Potection results *						compound		-
Formula       C19H20N202         Hill formula       C19H20N202         Average molar mass       308.3743         Monoisotopic mass       308.1325         Rem tag       #U& Anti-inflammatory         InCN       15x10:64.7x1.18(22)20         InCN       (15:10:64.7x1.15)22(19(17)23)         InCN       (15:10:64.7x1.15)22(19(17)23)         InCN       (15:10:64.7x1.15)22(19(17)23)         InCN       (15:10:64.7x1.15)22(19(17)23)         InCN       (15:10:64.7x1.15)22(19(17)23)         InCN       (15:10:64.7x1.15)22(19(17)23)         InCN       (15:10:64.7x1.12)22(19(17)23)         InCN       (15:10:64.7x1.15)22(19(17)23)         InCN       (15:10:64.7x1.12)22(19(17)23)         InCN       (15:10:64.7x1.12)22(19(17)23)         IncN       (15:10:64.7x1.12)22(19(17)23)         IncN       (15:10:64.7x1.12)22(19(17)23)         IncN       (15:10:64.7x1.12)2(19(17)23)         IncN       (15:10:64.7x1.12)2(19(17)23)         IncN       (15:10:64.7x1.12)2(19(17)23)         IncN       (15:10:64.7x1.12)2(10:10)         IncN       (15:10:64.7x1.12)2(10:10)         IncN       (15:10:64.7x1.12)2(10:10)         IncN       (15:10:64.7x1.12)2(10:10)			0					
Permuta       CLSH2/0X/02         Hill formula       CLSH2/0X/02         Average molar mass       308.3743         Monoisotopic mass       308.1525         Item tag       #filk, Anti-inflammatory         Item tag       #filk, Anti-inflammatory         InChl       15/C19H-20N202/c1-2-3-14-17-18(22)20         InChl       15/C19H-20N202/c1-2-3-14-17-18(22)20         InChl       15/C19H-20N202/c1-2-3-14-17-18(22)20         InChl       15-12-8-5-9-13-16/n4-13.17H/2-3.14H2_1H3         InChl       16-12-8-5-9-13-16/n4-13.17H/2-3.14H2_1H3         InChl       16-12-8-5-9-13-16/n4-13.17H/2-3.14H2_1H3         Inchl       Intersity         Retention technique       Intersity         Introduction technique       Intersity         Retention technique       Intersity         Petection resultis*       Andulation technique         Introduction technique       Intersity         Petetion result       Instrument model.         Instrument model.       Instrument serial noc., Unknown, Created by administrator on Mar 05, 2015         (5) items)       Cathartic         CAthartic       CNS stimulant         Contraceptive       Cathartic			II /		e-3,5-dione		NA AT SWA S	
Average molar mass 3083743 Monoisotopic mass 3081525 Rem tag ff.Bk. Anti-inflammatory InChi 15/C19H20N2O2/C1-2-3-14-17-18(22)20 InChi 15-10-6-4-7-11-55/21(19(17)23) InChi 15-10-6-		Antianginal				C19H20N2O2	mula	Formu
Average molar mass 308.3743 Monoisotopic mass 308.1525 Item tag fills, Anti-inflammatory InCh 15/C19H20N202/c1-2-3-14-17-18(22)20 InCh 25/C19H20N202/c1-2-3-14-17-18(22)20 InCh 25/C19H20N202/c1-				$\checkmark$		C19H20N2O2	formula	Hill fo
Monoisotopic mass       308.1525         Item tag       #Likk_Anti-inflammatory         InCN       IS/C194/20N2O2/c1-2-3.14.17.18(2220 (15-12-8-5-9-13-16/h4-13,17/4.2-3,144/2,1H3)         InCN       IS/C194/20N2O2/c1-2-3.14.17.18(2220 (15-12-8-5-9-13-16/h4-13,17/4.2-3,144/2,1H3)         ImCN       IS/C194/20N2O2/c1-2-3.14.17.18(2220) (15-12-8-5-9-13-16/h4-13,17/4.2-3,144/2,1H3)         ImCN       IS/C194/20N2O2/c1-2-3.14.17.18(220) (15-12-8-5-9-13-16/h4-13,17/4.2-3,144/2,1H3)         ImcN       ImcN         ImcN       Detail type         ImcN       Instrument model, Instrument serial no:, Unknown, Created by administrator on Mar 05, 2015 (5 items)         Imported from Excel       Imported from Excel         Imported from Excel						308.3743	erage molar mass	Avera
Item tag       #JUE, Anti-informatory         InCh       15/C19H20N202/c1-2-3-14-17-18(22)20         InCh       15-12-8-5-9-13-16/n4-13.17H2-3.14H2,1H3         InCh       16-12-8-5-9-13-16/n4-13.17H2-3.14H2,1H3         Inch       Inch         Inch       16-12-8-5-9-13-16/n4-13.17H2-3.14H2,1H3         Inch       Inch         <						308.1525	noisotopic mass	Mono
IS/C19H20N202/c1-2-3-14-17-18/22/20 (I5-10-6-4-7-11-15)2(19(17)23) 16-12-8-5-9-13-16/h4-13,17H2-3,14H2,1H3       Anti-hildsubetic         *       m       Anti-hildsubetic         Detection resultis*       Anti-hildsubetic         Initiation technique       Intensity       Retention time (min)         Detail type       Comment       Fragmentation type         Mass (m/z)       Adduct       Anti-bidsubetic         Anti-bidsubetic       Anti-hildsubetic       Anti-hildsubetic         Anti-bidsubetic       Anti-hildsubetic       Anti-hildsubetic         Anti-bidsubetic       Anti-bidsubetic       Anti-bidsubetic         Anti-bidsubetic       Anti-bidsubetic       Anti-bidsubetic         Anti-bidsubetic       Mass (m/z)       Adduct       Anti-bidsubetic         Anti-bidsubetic       Mass (m/z)       Adduct       Anti-bidsubetic         Bottection result       Instrument serial no:, Unknown, Created by administrator on Mar 05, 2015 (5 items)       Cathartic         CNS stimulant <td></td> <td></td> <td><math>\prec</math></td> <td></td> <td></td> <td>抗张 Anti inflammatony</td> <td></td> <td></td>			$\prec$			抗张 Anti inflammatony		
InChi (15-10-6-4-7-11-15)21(19(17)23) 16-12-8-5-9-13-16/h4-13,17H2-3,14H2,1H3				í Ì	19/22020		ntag	Item
16-12-8-5-9-13-16/h4-13,17h(2-3,14H2,1H3       Anti-inflammatory         Image: Section results       Anti-inflammatory         Image: Section results       Image: Section results         Image: Section results       Image: Section results         Image: Section results       Section results         Image: Section result       Section result         Image: Section result       Section result         Image: Section result       Section result         Section result       Section result         Image: Section result       Section result         Section result       Section result         Section result       Section result         Section result       Section result         Image: Section result       Section result         Section result       Section result         Section result       Section result         Image: Section resu			ò				hl	InChi
Anti-inflammatory     Anti-obesity		Antihypertensive	<b>~</b>		-3,14H2,1H3	16-12-8-5-9-13-16/h4-13,17H,2		
Anti-obesity     Anti-obesity     Anti-obesity     Anti-obesity     Anti-Parkinson age				$\checkmark$				
<ul> <li>Intersity</li> <li>Retention time (min)</li> <li>Detail type</li> <li>Comment</li> <li>Fragmentation type</li> <li>Mass (m/z)</li> <li>Adduct</li> </ul> Anti-Parkinson age           Inization technique         Intersity         Retention time (min)         Detail type         Comment         Fragmentation type         Mass (m/z)         Adduct         Antitussive         Antitusive         Antitusive         Antitussive								
Detection results •       Intensity       I Retention time (min)       Detail type       Comment       Fragmentation type       Mass (m/z)       Adduct       Antioyivic         Initiation technique       Intensity       I Retention time (min)       Detail type       Comment       Fragmentation type       Mass (m/z)       Adduct       Appetite suppress.         Imported from Excel       0.000       msE       Unknown       120.04435       Ch5 stimulant         ESt+       0.000       msE       Unknown       160.11210       Contractive	*							4
Detection results •       Intensity       Retention time (min)       Detail type       Comment       Fragmentation type       Mass (m/z)       Adduct       Anxiolytic         Imported from Excel       Instrument model:       Instrument serial no:       Unknown, Created by administrator on Mar 05,2015       (5 items)       Attention deficit hype       Attention deficit hype       Attention deficit hype       Cathartic       Cathartic         ESI+       0.000 m/s       Unknown       120,0435       Contractive       Contractive		Antipyretic			C. AAK.			
Ionization technique       Intensity       Retention time (min)       Detail type       Comment       Fragmentation type       Mass (m/z)       Adduct       Appetite suppress.         Imported from Escut       Instrument model:, Instrument serial no:, Unknown, Created by administrator on Mar 05, 2015 (5 items)       (5 items)       Bronchodilator       CAthartic       CNS stimulant         ESI+       0.000 msE       Unknown       120.0433       CNS stimulant       CNS stimulant		Antitussive					etection results •	Dete
ESI+       0.000 msE       Unknown       160.11210         FSI+       0.000 msE       Unknown       160.11210								
ESI+         0.000 msE         Unknown         120.04435         CNS stimulant           FSI+         0.000 msE         Unknown         160.11210         Constructive								14
Imported nom Excel         Cathartic           ESI+         0.000 msE         Unknown         120.04135         CAthartic           FSI+         0.000 msE         Unknown         160.11210         Contraceptive	eractivity disor		(2)	administrator on Mar 05, 201	nknown, Created by ac	t model: , Instrument serial no: , U	E Detection result	
FSI+ 0.000 msE Unknown 16011210 Contractive			<u> </u>			from Excel	Imported fr	
			435	Unknown	msE	0.000	ESI+	
			210	Unknown	msE	0.000	ESI+	
ESI+ 0.000 msE Unknown 309.15975 +H Cough suppressant		Cough suppressant	975 +H	Unknown	msE	0.000	FSI+	-
Decongetating							-	-
Est* 0.000 msc 0.000 msc 21100005 Effective dysfunction		Erectile dysfunction drug	200		mst	0.000	E2I+	
		Erectile dysfunction drug anal	700	Unknown	msE	0.000	ESI+	
		Estrogen antagonist						
	6	Estrogenic hormone						
Hypnotic Hypoglycemic								

Figure 3. This screen shows the infra-structure of the Synthetic Adulterants Library. A) Example screen capture for each of the compound entries. B) List of the pharmacological actions from the item tags.

For UPLC/Q-Tof MS experiments, MS<sup>E</sup> data acquisition mode was used for sample analysis, which in essence is a data independent acquisition strategy. From a single LC injection, the mass spectrometer is collecting data in two independent functions, one with collision energy set to low so that the MS full scan precursor ion information is collected, and another with collision energy set to high, so that corresponding MS/MS fragment ion information is collected. The two sets of data are connected and correlated by the LC retention time, as a result for each of the analytes in the sample, both MS and MS/MS information is obtained. Figure 4 shows the two UPLC/Q-Tof MS base peak ion (BPI) chromatograms obtained from the single injection on the test sample. Figure 4A is the BPI from the low CE scan, and Figure 4B is the BPI from the high CE scan.




Figure 4. The UPLC/Q-Tof MS BPI chromatograms of an anti-inflammatory capsule. 4A) BPI from a low CE scan; 4B) BPI from a high CE scan.

Data processing is automatic and requires minor parameter setting as templates are provided in the Natural Products Application Solution with UNIFI Adulterant Screening Application. The only user intervention required is to enable sample specific processing, to ensure that the correct analysis method is chosen, the peak processing time window matches the specific analysis, and to ensure that the Synthetic Adulterants Library is connected to the analysis method. The next step is for the user to go to the review page, click the Process tab, and wait for the result to display while all process steps take place automatically.

The steps involved after the Process button is clicked are as follows: 1. Peak picking based on 3D Apex Peak Detection, so a complete peak list is obtained for this sample. The peak picking happens simultaneously for both low CE MS full scan and high CE MS full scan mode. 2. Matching of the component list obtained from the Low CE MS full scan with the parent ion information that was obtained from the library. 3. Fragment ion confirmation by either matching with known key diagnostic fragments ions from the library, or matching with predicted fragment ions generated with MassFragment in high CE MS<sup>E</sup> full scan. MassFragment is an in-silico informatics tool which utilizes mol file structure of a given compound to predict possible fragmentation patterns based on the soft spot of that molecule. This is significantly helpful to confirm the correct match and to eliminate false positives.

Figure 5 shows a screen capture of the review window that displays results obtained at the end of process. This review window is consistent across UNIFI Scientific Information System. Results are organized in multiple segments within this window and discussed in detail below.



Figure 5. Results displayed in the Review tab within UNIFI Scientific Information System after processing. 5A) List of the available workflows. The Adulterant Screening Application provides a total of seven preset templates. Here, ADL refers to adulterant. 5B) Shows a list of components associated with the Good Match filter. 5C) XICs of m/z 309.1599 of the adulterant. 5D) MS spectra correlate to the XICs, both in low energy MS full scan and high energy MS<sup>E</sup> scan Figure 5A shows the available preset templates in the Adulterant Screening Application. As mentioned previously, for the Natural Products Application Solution with UNIFI, two complete sets of workflows are provided: the Ingredient Profiling Application<sup>2-4</sup> and the Adulterant Screening Application.

A set of 7 workflow templates is provided for the Adulterant Screening Application with the purpose of facilitating easy result review and confirmation. The System Suitability ensures a routine system check prior to analysis to ensure data quality. The Good Match lists all components (ion count above 5,000) that matched with the Synthetic Adulterants Library. Both parent ion (mass error <2mDa) and minimum of one diagnostic fragment ion must be present. The Tentative Match lists all components (ion count above 5,000) that match with the Synthetic Adulterants Library, parent ion only. The No Match High Intensity lists all components (ion count above 20,000) that did not match with the Synthetic Adulterants Library with ion count above 5,000. The Confirmed Table and Confirmed Plot are provided for quick review of all components that have been reviewed and confirmed by the user.

Figure 5B displays the list of components that correlate to each of the designated preset workflow templates. In this section, all critical information of the detected compound is listed such as expected neutral mass (Da), observed neutral mass (Da), mass error (ppm), observed retention time (minutes), response factor, and adduct ions. In this application example, for the herbal supplement we were analyzing, phenylbutazone is the only component listed under Good Match. Phenylbutazone is a nonsteroidal anti-inflammatory drug (NSAID) and has been banned for human use in US and UK as it can cause severe adverse effects such as suppression of white blood cell production and aplastic anemia.<sup>5</sup>

Figure 5C displays the extracted ion chromatogram (XIC) that correlates to the component displayed in Figure 5B. In this case, phenylbutazone from the Good Match template is selected in Figure 5B, therefore, the XIC associated with this component is displayed.

Figure 5D shows the MS spectra that correlate to the component listed in Figure 5B and the XIC displayed in Figure 5C. Here, the top spectrum is the MS full scan spectrum, and the bottom spectrum is the  $MS^E$  spectrum, both correlate to the 9.27 min peak from the XIC of m/z 309.1599. In the MSE spectrum, the blue mark indicates the fragment ion that matches the expected fragment list in the Synthetic Adulteration Library. For easy review, users can also choose to have all matched fragment ions listed as a table below the high energy spectrum, as shown in Figure 5D. For phenylbutazone, all expected fragments were observed in the high energy spectrum.

With the increasing trend in adulteration in herbal supplements, new or analogues of common synthetic adulterants are continually being created, as such, regardless of the size of the library, there will always be components that will not match. Any unmatched peaks that are in high abundance warrant further investigation. These peaks will be listed under the No Match High Intensity (Figure 6A and 6B). To further investigate unmatched high intensity components, the Structural Elucidation Tool6 can be used. The structural elucidation tool is easily accessible by right clicking and selecting Elucidate from the drop down list (Figure 6E). For this specific sample analysis, one component was listed under the No Match High Intensity at the retention time of 8.29 minutes with high intensity (Figure 6C).




Figure 6. High intensity component (Red Box in Figure 6C) from the No Match High Intensity preset template (Figure 6A) that did not match with the Synthetic Adulteration Library. The structure elucidation tools can be used by selecting the Elucidate option (Figure 6E). 6B Reveals the list of the components associated with each of the workflows. 6D) The low and high energy scan of the component selected from Figure 6B.

The key steps of elucidation are displayed in sequence in Figure 7. Step 1 is to determine the elemental composition of the component based on exact mass measurement. A unique feature in the UNIFI Scientific Information System for determining elemental composition is the consideration of the MS/MS fragment ions, in addition to the precursor ion exact mass and isotope distribution in the parameter settings (as displayed in Figure 7 Step 1).




Figure 7. Step by step process of the structure elucidation tool for the

identification and confirmation of the unknown component eluted at 829 an i-FIT confidence (%) is generated to show which formulas have a higher probability of being correct. In our sample analysis, we obtained the elemental composition match of  $C_{19}H_{20}N_2O_3$  with the highest i-FIT score of 99.86%.

Step 2 is to perform a library search from the on-line public database ChemSpider, which has compound entries from over 500 libraries. UNIFI Scientific Information System allows users to select searching parameters, and provides a direct link into ChemSpider. In the analysis, the ChemSpider search resulted in an initial match of oxyphenbutazone, which is the metabolite of phenylbutazone and is also an NSAID.

Step 3 is to validate and confirm the initial match with structural elucidation of fragment ions. This takes the advantage of the availability of the MS/MS fragment ions from the MS<sup>E</sup> scan and utilizes MassFragment. MassFragment is one of the structural elucidation tools that conducts calculations on any mol file structure in silico and predicts possible fragmentation patterns based on the weak bonds of the molecule. The predicted fragment ion is then compared with the fragment ions obtained from the MSE scan. This significantly helps to confirm the right match, and to eliminate false positives. Shown in Figure 7 Step 3, the possible fragments of oxyphenbutazone predicted by MassFragment were checked and matched with fragment ions obtained from the high collision energy scan of the same sample. The results show that key predicted fragments of oxyphenbutazone were found in a high CE MS<sup>E</sup> spectrum, which confirms the identified unknown peak as oxyphenbutazone.

As a result, two synthetic adulterants, phenylbutazone and oxyphenbutazone, were detected and identified in the herbal supplement sample. They both have pharmacological actions as NSAIDs. The final report of the analysis was then automatically generated using the report template, and is shown in Figure 8.

	Rome     Signature       Baport     3 of 5       New     Zoon       Layout     Sarch       Rese     Educion method
	Waters THE SCIENCE OF WHAT'S POSSIBLE"
50 Ar	
-AMATTIA	Table for Confirmed Adulterants

Figure 8. Summary report for the status of component identification, which is easily obtained by importing the natural products adulteration summary template

### Conclusion

The utility of the Natural Products Application Solution with UNIFI Adulterant Screening Application is demonstrated through the analysis of a herbal supplement product obtained from a street vendor. Two synthetic adulterants, phenylbutazone and oxyphenbutazone (both NSAIDS), were identified and confirmed from a single LC injection. The entire process from sample to report was completed in a couple of hours.

The Natural Products Application Solution with UNIFI Adulterant Screening Application contains a set of acquisition method templates, processing method template, Synthetic Adulterants Library, a set of dedicated workflows, and a report template, that allow a streamlined process from sample to report. Reliable answers about commercial products can be obtained quickly, without demands for a chemist's expertise or extensive previous related experience. This results in significantly enhanced efficiency and productivity for contract testing labs and regulatory agencies.

### References

- 1. Posadki P, et al. Contamination and adulteration of herbal medicinal products (HMPs): an overview of systematic reviews *et al. Eur J Clin Pharmacol.* 2013 Mar;69(3):295–307.
- Qiao L, Lewis R, Hooper A, Morphet J, Tan X, Yu K. Using Natural Products Application Solution with UNIFI for the Identification of Chemical Ingredients of Green Tea Extract. Waters application note. 2013. (p/n 720004837en).
- Qiao L, Lewis R, Hooper A, Morphet J, Tan X, Yu K. Using Natural Products Application Solution with UNIFI for the comparison for the Chemical Ingredients of Shuanghuanglian Oral Drink from Two Different Manufacturers. Waters application note. 2013. (p/n 720004842en).
- Qiao L, Lewis R, Hooper A, Morphet J, Tan X, Yu K. Using Natural Products Application Solution with UNIFI to Identify Chemical Ingredients and Deduce Possible Herbal Composition from Unknown Traditional Medicine Tablets. Waters application note. 2013. (p/n 720004840en).
- Inman WH. Study of fatal bone marrow depression with special reference to phenylbutazone and oxyphenbutazone. *Br Med J.* 1977 Jun 11;1(6075):1500–5.
- 6. Qiao L and Yu K. Using the elucidation tool in UNIFI scientific information system to identify unknown compounds in natural products. Waters application note. 2014. (p/n 720004876en).

## Featured Products

- ACQUITY UPLC I-Class PLUS System < https://www.waters.com/134613317>
- <u>Xevo G2-XS QTof Quadrupole Time-of-Flight Mass Spectrometry <https://www.waters.com/134798222></u>
- Natural Products Application Solution with UNIFI <a href="https://www.waters.com/134777097">https://www.waters.com/134777097</a>>

720005396, April 2015

 $\wedge$ 

©2019 Waters Corporation. All Rights Reserved.